Such-Lupe

Company profile

STADA - Corporate history

The most important milestones in the company’s history:

2011

  • Purchase of a branded product portfolio for the EU markets in Central Europe successfully concluded
  • Purchase of a generics business in Switzerland successfully concluded
  • STADA acquires British branded product Cetraben®

2010

  • Market capitalization on December 31, 2010: EUR 1.49 billion / Enterprise value:
    approx: EUR 2.4 billion

2009

  • Market capitalization on December 31, 2009: EUR 1.42 billion / Enterprise value:
    approx: EUR 2.3 billion

2008

  • Sales at record level for the thirteenth time in a row
  • Market capitalization on December 31, 2008: EUR 1.20 billion / Enterprise value:
    approx: EUR 2,2 billion

2007

  • Acquisition of the British Forum Bioscience group
  • Acquisition of the Russian MAKIZ group

2006

  • Acquisition of the Serbian Hemofarm Group
  • Sale of US subsidiary
 

2005

  • Acquisition of a package of eleven European branded products (amongst others Mobilat®)
  • STADA acquired a 58% stake in the Chinese pharmaceuticals manufacturing company BCP
  • Acquisition of the Portuguese generics supplier Ciclum Farma
  • Acquisition of approx. 97.5% of the shares in the Russian pharmaceuticals company, Nizhpharm

2004

  • Acquisition of a portfolio of Branded Products in Italy
  • De facto 1:1 stock split
  • Early Entry Mirtazapine

2003

  • Capital measures raised total net funds of EUR 256.4 million
  • Acquisition of a package of branded products from redinomedica, for the German OTC market
  • Acquisition of UK generics supplier Schein Pharmaceuticals with generics sales line Genus
  • Acquisition of 60% stake in Italy’s NPA, a sales specialist in the pharmacy sector
  • For the first time: Market capitalization > EUR 1 billion

2002

  • Start of operations in the USA with the sales company STADA Pharmaceuticals Inc. after acquiring the business of the US generics supplier MOVA Laboratories
  • Acquisition of marketing and sales activities of Italian pharmaceutical company Crinos
  • Acquisition of Spanish generics supplier Bayvit S.A.
  • STADA increases stake in Spanish brand supplier Ciclum Farma to 100%
  • Acquisition of numerous local branded products
  • Conversion from German accounting standards (HGB) to IAS
  • Inclusion in EuroSTOXX 600 stock index
 

2001

  • Sales exceed the EUR 500 million threshold
  • Conversion of preferred shares into registered common shares
  • STADA common stock is included in the German mid-cap index, MDAX
  • Majority investments in the Philippines (Croma Medic Ltd.)
  • Start-up of biogenerics cooperation with DSM, utilizing private venture capital

2000

  • Stock split 1:10 for common and preferred stock
  • Acquisition of Clonmel Healthcare Ltd., the leader in the Irish generics market

1999

  • Start-up of STADA Asiatic Co. Ltd., Bangkok
  • Investment in Spain in Ciclum Farma, Madrid
  • Start-up in Italy with EG S.p.A., Milan

1998

  • Conclusion of the process of going public with registered common stock
  • Acquisition in Denmark (PharmaCoDane Aps)
  • Positioning as comprehensive supplier in the health care market with the acquisition of oncologics (cell pharm) and a package of discretionary prescription brands from Fresenius

1997

  • Beginning of process of going public with non-voting preferred stock

1996

  • Purchase of ALIUD PHARMA as second generics line in Germany
  • Expansion into France (EG Laboratoires EuroGenerics S.A.) and the Czech Republic (ALIUD PHARMA CZ s.r.o.)

1995

  • Expansion of the STADA Group structure with market-oriented sales companies

1992

  • Start-up in Asia with STADA Pharmaceuticals (Asia) Ltd. in Hong Kong

1991

  • Acquisitions in the Netherlands (Centrafarm B.V.) and in Belgium (N.V. Eurogenerics S.A.)

1986

  • Beginning of internationalization (Helvepharm AG/Switzerland, STADA Arzneimittel/Austria)
 

1975

  • Entry into the emerging generics market

1970

  • STADA becomes a stock corporation with registered shares exclusively for pharmacists

1956

  • Move to the present location in Bad Vilbel

1948

  • New beginning at the locations in Essen and Tübingen with products for self-medication

1895

  • Founded in Dresden as a pharmacists’ cooperative
Zurück
Here you can read an online version of the last 4 financial reports on your screen, download the PDF or order a hard copy. Older financial reports are available in PDF format from our archive. More
Here you will find corporate news and ad-hoc releases that you can read directly on your screen or download as a PDF file. Older releases are available for you in our archive. More
The current STADA share price with share price chart including Excel download and market capitalization of STADA Arzneimittel AG are available here. We also offer you an interactive peer group share price comparison. More
Here you will find photos (available in two resolutions) of the STADA Executive Board, buildings, flags and STADA Arzneimittel AG production facilities, which you may download in unchanged form for your press work. More

 

(c) 2012 STADA Arzneimittel AG, Stadastraße 2-18, 61118 Bad Vilbel, Telefon 06101 603-0, Fax 06101 603-259, e-Mail: info@stada.de